Table 1.
Patient characteristics
| Age at diagnosis | p | ||
|---|---|---|---|
| Diagnosis at ≤90 n (%) n = 12,722 (99.4%) | Diagnosis at >90 n (%) n = 113 (0.6%) | ||
| Age at diagnosis (years) | |||
| Median | 62 | 92 | |
| Range | 0–90 | 91‐101 | |
| Sex | NS1 | ||
| Female | 6,283 (49·4%) | 62 (54·9%) | |
| Male | 6,439 (50·6%) | 51 (45·1%) | |
| Localization at diagnosis | |||
| Trunk | 6,706 (52·7%) | 25 (22·1%) | ≤0.0011 |
| Limb | 4,218 (33·2%) | 67 (59·3%) | |
| Superior limb | 1,092 (8·6%) | 22 (19·5%) | |
| Inferior limb | 3,126 (2·6%) | 45 (3·8%) | |
| Head & neck | 710 (5·5%) | 18 (15·9%) | |
| Unknown | 1,088 (8·6%) | 3 (2·7%) | |
| Histology | |||
| Complex genomics | 8,431 (66·3%) | 104 (92·0%) | ≤0.0011 |
| UPS | 1,569 (12·3%) | 40 (35·4%) | |
| LMS | 2,762 (21·7%) | 16 (14·2%) | |
| Myxofibrosarcoma | 804 (6·3%) | 14 (12·4%) | |
| Angiosarcoma | 666 (5·2%) | 12 (10·6%) | |
| DDLPS | 1,506 (11·8%) | 11 (9·7%) | |
| Undifferentiated sarcoma | 768 (6·0%) | 10 (8·8%) | |
| Rhabdomyosarcoma | 98 (0·7%) | 1 (0·9%) | |
| Fibrosarcoma | 44 (0·3%) | 0 (0%) | |
| Liposarcoma pleomorphic | 174 (1·4%) | 0 (0%) | |
| Osteosarcoma | 40 (0%) | 0 (0%) | |
| GIST | 1,490 (11·7%) | 6 (5·3%) | |
| Translocation sarcoma | 2,801 (22·0%) | 3 (2·7%) | |
| Ewing | 769 (6·0%) | 1 (0·9%) | |
| Myxoid LPS | 484 (3·8%) | 1 (0·9%) | |
| Synovial sarcoma | 635 (5·0%) | 1 (0·9%) | |
| ESS | 273 (2·1%) | 0 (0%) | |
| Epithelioid hemangioendothelioma | 100 (0·9%) | 0 (0%) | |
| EMC | 89 (0·7%) | 0 (0%) | |
| SFT | 451 (3·5%) | 0 (0%) | |
| Grade | |||
| 1 | 1,086 (8·5%) | 6 (5·3%) | NS1 |
| 2 | 3,133 (24·6%) | 24 (2·2%) | |
| 3 | 3,800 (29·9%) | 39 (34·5%) | |
| Unknown | 4,703 (36·9%) | 44 (38·9%) | |
| Depth | <0.0011 | ||
| Superficial | 1873 (14·7%) | 45 (39·8%) | |
| Deep | 8,636 (67·9%) | 50 (44·2%) | |
| Superficial + deep | 806 (6·3%) | 13 (11·5%) | |
| Unknown | 1,407 (11·1%) | 5 (4·4%) | |
| Size | NS1 | ||
| <50 mm | 1,620 (12·7%) | 18 (15·9%) | |
| ≥50 mm | 3,924 (30·8%) | 29 (25·7%) | |
| Unknown | 7,178 (56·4%) | 66 (58·4%) | |
| Previous history of radiotherapy | NS1 | ||
| No | 12,388 (97·7%) | 110 (97·3%) | |
| Yes | 294 (2·3%) | 3 (2·7%) | |
| Previous history of cancer | NS1 | ||
| No | 8,563 (67·3%) | 68 (60·2%) | |
| Yes | 1,741 (13·7%) | 20 (17·7%) | |
| Unknown | 2,418 (19·0%) | 25 (22·1%) | |
| Known genetic predisposition | NS1 | ||
| No | 10,181 (80·0%) | 88 (77·9%) | |
| Yes | 123 (1·0%) | 0 (0%) | |
| Unknown | 2,418 (19·0%) | 25 (2·1%) | |
| Metastatic at diagnosis | 0.0091 | ||
| Yes | 1865 (14·7%) | 6 (5·3%) | |
| No | 9,664 (76·0%) | 89 (78·8%) | |
| Unknown | 1,193 (9·4%) | 18 (15·9%) | |
Italics refer to molecular subtypes of sarcomas.
1
Chi2 test.